New patent for Glenmark Specialty drug RYALTRIS

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/

Annual Drug Patent Expirations for RYALTRIS
Annual Drug Patent Expirations for RYALTRIS

Ryaltris is a drug marketed by Glenmark Specialty and is included in one NDA. It is available from one supplier. There are twelve patents protecting this drug.

This drug has sixty-five patent family members in twenty-eight countries.

The generic ingredient in RYALTRIS is mometasone furoate; olopatadine hydrochloride. One supplier is listed for this compound. Additional details are available on the mometasone furoate; olopatadine hydrochloride profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

» Start Your Free Trial Today «

Copyright © DrugPatentWatch. Originally published at
DrugPatentWatch - Make Better Decisions
Scroll to Top